Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results

Slides:

Advertisements

Similar presentations

Mark Pletcher 6/10/2011 Quantifying Treatment Effects.

Advertisements

How to assess an abstract

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.

Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.

1 Novel Oral Anticoagulants: Benefits and risks Matthew Moles, MD December 4, 2012 University of Colorado.

Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,

Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.

ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?

BS Evidence Based Medicine And Atrial Fibrillation.

Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.

Rohan Subasinghe.  Non valvular aF increases with age from 0.5 % at age to 9 % at age  AF is an independent Risk factor for CVA  Patients.

Randomized Evaluation of Long- term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke.

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

The case for switching to the emerging oral anticoagulants in Atrial Fibrillation Dr Neil Baldwin Consultant Physician & Clinical Lead for Stroke North.

UK/CVS (1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS (1) | Date of preparation: February 2013.

Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.

How to Analyze Therapy in the Medical Literature (part 2)

Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)

Measures of Association Professor Mobeen Iqbal Shifa College of Medicine.

EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Which Treatment ? For a patient, 64-year-old male For a patient, 64-year-old male No HT, DM, Heart failure, LV dysfunction No HT, DM, Heart failure, LV.

Update in ESC: Dabigatran among OAC

Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.

Centre for Evidence-Based Medicine EBM and E-B Guidelines l EBM integrates evidence, expertise, and the unique biology and values of individual patients.

Polypill x Aspirin Project Groups 3 and 4

Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.

EBM --- Journal Reading Presenter ：林禹君 Date ： 2005/10/26.

Critical appraisals: Treatment. CLINICAL TRIAL = a prospective study comparing the effect and value of intervention(s) against a control in human beings.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Number Needed to Treat Alex Djuricich, MD Indiana University School of Medicine Department of Medicine Ambulatory Rotation

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.

EBM R1張舜凱.

HelpDesk Answers Synthesizing the Evidence

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

EBM Workshop: Treatment

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Update on the Watchman Device CRT 2010 Washington, DC

Occlusion: Patient Selection Are the Data Supportive?

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

Efficacy and Safety of Dabigatran vs

Anticoagulation in Atrial Fibrillation

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Randomized Evaluation of Long-term anticoagulant therapY

ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.

مقدمه‌ای بر طب مبتنی بر شواهد

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

remember to round it to whole numbers

Relative Risk of Events by CHA2DS2-VASc Score

Relative risk of major events with atenolol vs placebo

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism.

Atrial Fibrillation.

1 Information Mastery Skills Calculating RR, RRR, ARR and NNTs A. Bornstein, MD, FACC Assistant Professor of Medicine Weil Cornell Medical College New.

Study Background and Rationale Updated October 24, 2018

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

ACC 2003 Late Breaking Trials

EBM – therapy Dr. Tina Dewi J , dr., SpOG

How to assess an abstract

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Presentation transcript:

Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results Outcome Event rate RRR ARR Time (yrs) NNT 95% CI Warfarin Dabi 150 mg Stroke embolism 3.3% 2.2% 33.3% 1.1% 2 91 59 – 194 Connolly SJ NEJM 2009 For this outcome the intervention shows benefit. (ARR = absolute risk reduction, RRI = relative risk reduction, NNT = number needed to treat)

Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results Outcome Event rate RRI ARI Time (yrs) NNH 95% CI Warfarin Dabi 150 mg Serious AEs 1.7% 2.7% 56.7% 1% 2 101 66 – 217 Connolly SJ NEJM 2009 For this outcome the intervention shows harm. (ARI = absolute risk increase, RRI = relative risk increase, NNH = number needed to harm)